

COVID-19 adaptive humoral immunity models: weakly neutralizing versus antibody-disease enhancement scenarios

Antoine Danchin^{*†}, Oriane Pagani-Azizi[‡], Gabriel Turinici[§],
Ghozlane Yahiaoui[¶]

Jan 2022

Abstract

The interplay between the virus, infected cells and the immune responses to SARS-CoV-2 is still under debate. Extending the basic model of viral dynamics we propose here a formal approach to describe the neutralizing versus weakly (or non-)neutralizing scenarios and compare with the possible effects of antibody-dependent enhancement (ADE). The theoretical model is consistent with data available from the literature; we show that weakly neutralizing antibodies or ADE can both give rise to either final virus clearance or disease progression, but the immuno-dynamic is different in each case. Given that a significant part of the world population is already naturally immunized or vaccinated, we also discuss the implications on secondary infections following vaccination or in presence of immune system dysfunctions.

1 Background

SARS-CoV-2 is a new virus from the coronavirus family, responsible for the ongoing COVID-19 pandemic. To date, there are more than 300 million cases and over five million deaths worldwide [1]. SARS-CoV-2 is the third betacoronavirus to severely infect humans appearing in the last 20 years, after SARS-CoV-1 and MERS-CoV. This motivates a growing need for efficient drugs and/or vaccines, not only for the time being but also in anticipation of a future coronavirus resurgence.

*The order of the authors is alphabetic

†Institut Cochin, Paris, France. Antoine.Danchin@normalesup.org

‡CEREMADE - ESPCI Paris PSL, Paris, France. Oriane.Pagani-Azizi@espci.fr

§Université Paris Dauphine - PSL Research University, Paris, France.

Gabriel.Turinici@dauphine.fr

¶Mathematical Institute, University of Oxford, Oxford, United Kingdom.

Ghozlane.Yahiaoui@maths.ox.ac.uk

However, initial promising successes of antiviral treatments raised also the possibility of negative side-effects. On the vaccine front, an auto-immune disease (leading to temporary suspension of clinical trials) appeared during the AstraZeneca vaccine trial (Sept 9th 2020); altogether this context demonstrated the importance of understanding qualitatively and quantitatively the immune response to primary infection and also to challenges (vaccines belong to both categories). In particular, relevant mathematical models of the immune dynamics can be of interest to understand and predict the complicated behavior often observed.

We focus here on adaptive humoral immunity (the antibody-mediated immunity) and refer to future works for an extension to the cellular and/or innate immune system.

For clinical reasons and also for the understanding of those studying vaccines, antibody responses are of paramount importance. However, the neutralization capacities of antibodies is still under discussion, especially since weak or non-neutralizing antibodies can promote infection through a process called antibody-dependent enhancement (hereafter abbreviated 'ADE') [2, 3, 4, 5] (see appendix A.1 for details); thus the antibody neutralization capacity and ADE level are important ingredients of the model. Furthermore, such behavior may be accentuated by a challenge (secondary infection or infection following some immune system event or dysfunction), cf. also appendix A.2. Accordingly, we investigated here both primary and secondary COVID-19 infections.

To summarize, we propose a mathematical model of the immune response and virus dynamics that includes the possibility of weakly neutralizing antibodies and / or ADE. and analyze its implications. At the time of writing the final draft (January 2022) a significant part of the world population is either vaccinated or naturally immunized and the consequences of reinfection events are a major source of uncertainty concerning pandemic evolution. This naturally calls for scientific investigation.

2 Methods

2.1 Mathematical model

We present below the viral and immune response model. It is a compartmental model similar to those used to describe the epidemic propagation, see [6, 7, 8, 9] for a general introduction and [10, 11, 12, 13, 14, 15] for COVID-19 specific works.

The viral-host interaction (excluding the immune response) is called the basic model of virus dynamics. It has been extensively validated both theoretically and experimentally, see [16, eq (3.1) page 18], [17, eqns. (2.3)-(2.4) page 26] and references therein. See also [18, 19, 20] for general overviews of mathematical immunology.

The model involves several classes: that of the target cells, denoted T , the infected cells, denoted I , the free virus denoted V and the antibodies denoted

A. The model is illustrated in figure 1.




Figure 1: Graphical illustration of the flow in the model (1)-(5).

Target cells T , which in our case are the epithelial cells with ACE2 receptors located, for instance in the respiratory tracts including lungs, nasal and trachea/bronchial tissues, are produced at a rate Λ and die at rate μ . The parameters Λ and μ define tissue dynamics in the absence of infection, see also section D.1. When these susceptible cells meet free virus particles V , they become infected at a rate β_0 . Furthermore, target cells can also become infected via ADE if virus entry is mediated by antibodies. The parameter β_1 represents the rate of ADE infection route which is the result of a three-species interaction: T , A and V .

Infected (initially target) cells, denoted I , die at a rate δ . Note that this death rate will often be larger than the death rate of uninfected cells because viruses cause cell damage and cell death, [17, 16]. Infected cells produce new virus particles at a rate ω , and the free virus particles which have been released from infected cells decay at a rate c called the clearance rate.

Free virions are neutralized by antibodies A , which can block virus entry into cells but also facilitate phagocytosis, at a rate b . Finally, the antibodies can be stimulated by the free virus with a production rate a while declining at a rate of σ (see for instance [17, eq. (9.4) p.126]). Note that alternative proposals for the antibody dynamics exist, see e.g. André and Gandon [21] who assume that immune response, once started, grows at a constant rate while Pawlek et al. [22] design a more complex model that takes into account the macrophage

activation. The complete model reads (all constants are positive):

$$dT/dt = \Lambda - \mu T - \beta(A)VT \quad (1)$$

$$dI/dt = \beta(A)VT - \delta I \quad (2)$$

$$dV/dt = \omega I - cV - bAV \quad (3)$$

$$dA/dt = aVA - \sigma A \quad (4)$$

$$\beta(A) = \beta_0 + \beta_1 A. \quad (5)$$

Several hypotheses in this model need to be further documented. The first one is that all infected cells including ADE infected cells support viral replication and can produce virus. However, to date, it is still unclear whether ADE infected cells can support viral replication in vivo, [4], [5]. Here we choose not to distinguish between virus productive and non productive infected cells to keep the model simple (see however the comments in appendix E). For the same reason, we do not discriminate between neutralizing, weakly neutralizing or non-neutralizing antibodies but consider all as members of the same class, the antibodies neutralizing capacity will therefore be the average of the neutralizing power and the average is described by the parameter b ; on the other hand the ADE magnitude will be monitored by parameter β_1 . These parameters are the most important part of the immune response and the object of our study.

3 Stability of equilibria and further considerations

We operate under the assumptions that all parameters are positive and furthermore the following two assumptions hold (see Appendix D for details):

$$\text{Assumption 1: } \delta > \mu. \quad (6)$$

$$\text{Assumption 2: } (R_0 - 1) \frac{\mu}{\beta_0} > \frac{\sigma}{a}. \quad (7)$$

where we define as in [16, eq. (6.2) page 53]):

$$R_0 = \frac{\beta_0 \omega \Lambda}{c \delta \mu}. \quad (8)$$

Note that (7) implies in particular $R_0 > 1$ which is a standard condition for such models. We will further denote

$$V^{is} := (R_0 - 1) \frac{\mu}{\beta_0}, \quad V^t := \sigma/a. \quad (9)$$

3.1 Stability of the equilibrium without ADE

With these definitions we can give the main theoretical properties of the model depending on the presence or not of the ADE term.

Proposition 1. *The model (1)-(4) without ADE i.e., $\beta(A) = \beta_0$ (that is $\beta_1 = 0$) has a single stable equilibrium given by:*

$$T = T^{is} := \frac{\Lambda}{\mu + \beta_0 V^t}, \quad I = \frac{\beta_0 \Lambda V^t}{\delta(\mu + \beta_0 V^t)}, \quad V = V^t, \quad A = \frac{c(V^{is} - V^t)}{\beta_0 b(\mu + \beta_0 V^t)}. \quad (10)$$

Proof. The proof of the stability of the equilibrium (10) is technical and is given in full detail in the appendix D.3. \square

3.2 Stability of the equilibrium with ADE

We investigate now the full model having a non-null ADE term $\beta_1 > 0$.

Proposition 2. *The model (1)-(4) has three equilibria:*

1. *the trivial equilibrium $T = T^* = \Lambda/\mu$, $V = I = A = 0$ which is unstable;*
2. *the immunosuppression equilibrium, also unstable, given by :*

$$T = T^{is} = \frac{\delta c}{\beta_0 \mu}, \quad V = V^{is} := (R_0 - 1) \frac{\mu}{\beta_0}, \quad I = I^{is} := (R_0 - 1) \frac{c\mu}{\omega \beta_0}. \quad (11)$$

3. *and a third equilibrium characterized as follows:*

- *the antibody level A^f is the unique positive solution of the following second order equation in the unknown A :*

$$\omega \beta(A) \Lambda = \delta(c + bA)(\mu + \beta(A)V^t); \quad (12)$$

- *the other quantities are :*

$$T^f = \frac{\delta(c + bA^f)}{\omega \beta(A^f)}, \quad I^f = \frac{V(c + bA^f)}{\omega}, \quad V = V^t = \frac{\sigma}{a}. \quad (13)$$

The following affirmations hold true concerning this third equilibrium

- (a) *when β_1 is small enough the equilibrium is stable;*
- (b) *when β_1 is large enough the equilibrium is stable;*
- (c) *however there exist choices of parameters (in particular values of β_1) for which this equilibrium is unstable.*

Proof. The proof is presented in appendix D.4. \square

3.3 Dynamical aspects

The equilibrium analysis in the previous sections does not yet tell the full story of the evolution of the system (1)-(4). Depending on the parameters, a common behavior is the following: initially A will increase as response to V being above threshold V^t ; the increase of A will drive both I and V to zero. Such a dynamics is stable over a long period and in practice I and V will keep small values for a time long enough to ensure virus clearance (when V is small enough, due to the random nature of the events, V will disappear).

Taking I and V to be constant equal to zero, the new evolution is:

$$dT/dt = \Lambda - \mu T \quad (14)$$

$$dA/dt = -\sigma A. \quad (15)$$

Note that equations for I and V are missing because if the initial states are $V(0) = I(0) = 0$ then $V(t) = I(t) = 0$ for all $t \geq 0$. This evolution drives T to Λ/μ and A to zero. If however during the slow decay of A a challenge is presented in the form of a virus load $V > \sigma/a$ a new infection will start and V and I will rise again.

In conclusion, the stable equilibrium (12)-(13) is not necessarily reached in practice. The precise dynamics depends crucially on the parameters b and β_1 , see main text for details.

4 Results

4.1 Theoretical results

We refer the reader to the section 3 for the rigorous statements concerning the theoretical properties of the model (1)-(5). Several situations may occur, but in summary the absence of ADE (i.e., $\beta_1 = 0$) insures stable equilibrium while intermediate β_1 values (neither too small not too large) may provide examples of unstable equilibria; moreover, stochastic events prevent the stable equilibrium state to be reached in practice, cf. section 3.3. The parameters b and β_1 are shown to be the most important for the viral-host-antibody dynamics.

4.2 Empirical results: initial infection

Taking into account the available data from the literature and the methodology in appendix B we run a numerical procedure to fit the model parameters to reproduce at best the viral load data in figure 2 (left) and obtained the values in table 1. The numerical simulation for a primary infection corresponding to these parameters is shown in figure 3.

There is a 20% fall of target cells which either become infected or naturally die. The viral load peaks around 4-5 days after symptoms onset at 1.8×10^6 copies/ml. While SARS-CoV-1 viral load, as MERS-CoV, peaked around 10 days after symptoms onset, most studies agree that SARS-CoV-2 viral load




Figure 2: **Left:** Clinically observed typical variation of SARS-CoV-2 viral load in nasopharyngeal swab normalised using cell quantification. Data taken from [23, figure 3 page 703, patient 4]. **Right:** Typical time variations for IgG. Data taken from [24, figure 2 page 1085]. Note that the antibody data is a mean over several days and corresponds to a different patient cohort.

μ	Λ	ω	β_0	β_1	δ	c	b
9.66	9.66×10^6	59.74	1.28×10^{-6}	0	16.22	1.45	0.52
a	σ	$I(0)$	$V(0)$	$A(0)$			
9.15×10^{-7}	0.02	372.11	994.84	1.17			

Table 1: Baseline parameters use in numerical simulations of the model (1)-(4).




Figure 3: Numerical simulation of the first infection without ADE for model (1)-(4) and parameters in table 1. A good fit for the viral load from figure 2 is obtained (data is truncated below the value 1). On the contrary the fit is not as good for $A(t)$ because data does not correspond to the same patient (joint $V(t)/A(t)$ data was not available).

peaks sooner, around 5 days, [23],[25]. Concerning antibodies, they increase sharply until week 2 then slower until a month after infection and start to decrease within 2-3 months [26], [27]. Qualitative agreement is observed with clinically observed variations variations of viral load and partially with antibodies concentration depicted in figure 2 (see references in the figure).

Note that, although we expect agreement between $V(t)$ and the viral load evolution in figure 2 (left) (which corresponds to a precise, real patient) the antibody data from [24, figure 2 page 1085] does not correspond to the same patient (data unavailable) but is a mean value over several days and patients (not always the same). Each individual is likely to have his own immuno-kinetic parameters: the parameters of the individual that may fit the $A(t)$ data from figure 2 (right) are not the same as the parameters that fit the data in left side of the same figure.

The equilibrium state (10) when $\beta_1 = 0$ (no ADE present) is reached after 2 years for all variables in figure 3. However, viral load and infected cells reach a minimum within several weeks post-infection before increasing and oscillating toward equilibrium state (10) (simulations not shown here). Therefore, if the virus load is very small close to the minimum, all other variables decrease towards 0 and the infection has vanished. The equilibrium state (10) is stable but not reached in practice as the patient is cured.

4.3 Empirical results: secondary infection, variants, vaccination

We focus on a scenario where the immuno-kinetic parameters such as the neutralizing efficacy (b) or the ADE parameter (β_1) change; the causes can be multiple: a primary infection with a different variant, vaccination, or some immune evolution (aging being an example). In all cases we investigate the infection, called challenge, that takes place with a different set of b or β_1 parameters than in table 1.

4.3.1 Variation of the neutralizing capacity b

When there is no ADE, decreasing the neutralizing capacity of antibodies (parameter b) leads on the one hand to a higher viral load peak but on the other hand to higher antibodies concentrations. The less neutralizing the more abundant antibodies are to compensate so that the infection is always solved. The simulation results are presented in figure 4. Infection resolution is obtained with little target cell destruction for larger values of b . On the contrary, low values of b will lead to significant increase of the antibody number and simultaneous decay of target cells, both largely pejorative for the patient.

In the cases where the viral load reaches low values the infection stops before converging to the theoretical equilibrium.

4.3.2 Presence of ADE ($\beta_1 > 0$)

We investigated in figure 5 the possibility of the ADE mechanism present ($\beta_1 > 0$), for a range of possible parameter β_1 values. We plot all variables upon challenge with the same neutralizing capacity for antibodies. A higher ADE parameter leads to more destroyed target cells, more infected cells, more viral load and more antibodies. However the antibodies concentration is restricted by an upper limit. There is a threshold effect : increasing β_1 does not increase significantly the antibody population (see figure 5 and compare with theoretical insights in the proof of point 3b of proposition 2 in Appendix D). Therefore a higher β_1 ADE parameter cannot be compensated by more antibodies. For example, unlike $\beta_1 = 10^{-8}$, if $\beta_1 = 10^{-6}$ the viral load directly stabilizes to its equilibrium state (13), without reaching a minimum close to 0 while oscillating (simulation not shown here). In this case, the infection wins (leading to respiratory function disruption and possibly patient death). Large values of β_1 lead to significant (possibly total) destruction of target cells.

5 Discussion

We investigated the immune response to SARS-CoV-2 infection and re-infection through a numerical model; the model can also take into account the possible presence of ADE, either on first infection or to a challenge (secondary or re-infection with a different phenotype, after vaccination, etc.).




Figure 4: Numerical simulation of the model (1)-(4) and parameters in table 1. Only the neutralizing capacity b is changed around the nominal value $b = 0.52$. Lower value of the neutralizing capacity b (solid blue line) leads to lower target cell count and higher antibody levels. See figure 6 for simulation over a longer time span.




Figure 5: The effect of the ADE parameter β_1 (the model (1)-(4)). The secondary (challenge) infection has fixed neutralizing antibodies capacity b but several possible β_1 (ADE) parameter values; for all other parameters we use the nominal values given in table 1. See figure 7 for simulation over a longer time span.

As to date there is no clear evidence that ADE occurs in COVID-19 severe patients, we assume that ADE only happens upon challenge.

We started from a classic viral-host dynamics ([17],[28]) that we modified by adding parameter β_1 to account for a possible ADE mechanism. In order to keep the model at its lowest complexity, we do not distinguish between ADE triggering antibodies and neutralizing antibodies.

We conducted a theoretical study of our system by computing equilibrium states and stability with and without ADE. We showed that stochastic events may also play a role and prevent the stable equilibrium state to be reached in practice; we identified the parameters b (neutralization capacity) and β_1 (ADE presence) to be crucial for the dynamics of our system.

Then, we calibrated our parameters values to match reference viral load from the literature [23, 27] and obtained good results.

We then investigated a secondary infection (or infection following vaccination or other immune event) that can possess different immuno-dynamic parameters. We saw that without ADE, the possible weak antibody neutralizing capacity was systematically compensated with higher concentrations of antibody leading to viral clearance. On the other side, adding ADE was not always associated with viral clearance but possibly high target cell destruction. Simulations and equilibrium analysis showed that antibody concentration had an upper limit which prevented higher ADE to be compensated by an unlimited antibody quantity. Therefore, ADE should be taken in consideration as a serious risk in disease understanding, treatment and vaccine development and scheduling.

On the other hand, we showed that the results are sensitive to the neutralizing antibody capacity (the b parameter); note that a decrease of this parameter can occur in several situations, for instance due to immune function decay, due to the malfunctioning of the antibody immunodominance mechanism that ends up selecting too many weakly neutralizing antibodies or due to miscalibrated therapeutic interventions. Independent of the cause, such a decrease of the neutralizing capacity is susceptible to imply a substantial deterioration of the outcome.

In summary, our results seem to support a picture where ADE presence is primary correlated with important target cell destruction while loss in neutralization capacity is correlated with both higher antibody count (leading to inflammation) and larger target cell destruction.

5.1 Limitations and future work

As any other, our model contains of course several limitations. First, we considered all infected cells to support viral replication, including ADE-infected cells. Concerning SARS-CoV-2, the questions of ADE is still under debate, but for SARS-CoV-1 in vitro ADE evidence suggested abortive viral replication in ADE infected cells. Therefore, if we changed the model (1)-(4) to include this distinction, equilibrium state would change and ADE may be compensated. Similarly, we did not distinguish between former antibodies and novel antibodies secreted upon challenge. This would imply more parameters and change equilibrium

levels but without inherently changing variables behavior. The antibody dynamic model can also be changed to include e.g., constant antibody production following a threshold or more specific effects [21, 22]. Regarding parameters, we did not have enough exploitable available data to train our model and fit parameters better. Finally, an unique model can hardly capture the extreme variability of COVID-19 clinical outcomes, see [29]; some studies proposed that some of the variability come from genetics, see e.g., [30] where genetic information from roughly 4,000 people from Italy and Spain was correlated to severity of COVID-19. This may lead to a variability of our model parameters in the form of random variables.

By now (January 2022), billions of people have been vaccinated, at least by one injection, and more than half a billion have been infected. Fortunately, despite the spread of the highly contagious omicron variant, it appears that morbidity and mortality are declining. This implies that, for the time being, the most disastrous consequences of the phenomena included in this model are not being observed. However, it must be emphasized that human polymorphism, viral polymorphism and highly variable environmental conditions, as well as the considerable variety of vaccination protocols, mean that there may be isolates where ADE or the other immune responses we have explored could be significant. It is therefore particularly important to monitor variations in morbidity and mortality around the world so that a rapid response can be implemented if there is any local increase. Finally, the types of vaccines used are very different. For those based on well-established technologies, we do not foresee any consequences other than those discussed in this work, except perhaps as a function of the vaccination protocols (time lag between primary and booster injections). In contrast, the use of vaccines based on indirect antigen production (adenovirus- or synthetic RNA-based vaccines) requires specific encapsulation of the active ingredient in a variety of capsules or cassettes. These containers can, by themselves, be immunogenic. The consequence would be that after several immunisations, patients would develop a response against the vaccine, rendering it ineffective against the disease. We did not consider this outcome in our work.

The more science will shed light on the full picture of SARS-CoV-2, the more our model can input complex and precise details. In the meantime, the main take-home message is that, with parameters consistent with the available clinical data, the neutralizing capacity and ADE mechanisms may play an important immunological role into the primary and secondary infection outcomes.

Acknowledgements

Ghozlane Yahiaoui is supported by the Engineering and Physical Sciences Research Council (EPSRC): CDT Grant Ref. EP/L015811/1.

References

- [1] John's Hopkins University. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. <https://coronavirus.jhu.edu/map.html>.
- [2] Adam Taylor, Suan-Sin Foo, Roberto Bruzzone, Luan Vu Dinh, Nicholas J. C. King, and Suresh Mahalingam. Fc receptors in antibody-dependent enhancement of viral infections. *Immunological Reviews*, 268(1):340–364, November 2015.
- [3] Akiko Iwasaki and Yexin Yang. The potential danger of suboptimal antibody responses in COVID-19. *Nature Reviews. Immunology*, 20(6):339–341, 2020.
- [4] Ming Shum Yip, Nancy Hiu Lan Leung, Chung Yan Cheung, Ping Hung Li, Horace Hok Yeung Lee, Marc Daëron, Joseph Sriyal Malik Peiris, Roberto Bruzzone, and Martial Jaume. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. *Virology Journal*, 11:82, May 2014.
- [5] Martial Jaume, Ming S. Yip, Chung Y. Cheung, Hiu L. Leung, Ping H. Li, Francois Kien, Isabelle Dutry, Benoît Callendret, Nicolas Escriou, Ralf Altmeyer, Beatrice Nal, Marc Daëron, Roberto Bruzzone, and J. S. Malik Peiris. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc γ R pathway. *Journal of Virology*, 85(20):10582–10597, October 2011.
- [6] W. O. Kermack and A. G. McKendrick. A contribution to the mathematical theory of epidemics. *Proc. R. Soc. Lond., Ser. A*, 115:700–721, 1927.
- [7] Odo Diekmann and Johan Andre Peter Heesterbeek. *Mathematical epidemiology of infectious diseases: model building, analysis and interpretation*, volume 5. John Wiley & Sons, 2000.
- [8] Herbert W. Hethcote. The mathematics of infectious diseases. *SIAM Rev.*, 42(4):599–653, 2000.
- [9] Tuen Wai Ng, Gabriel Turinici, and Antoine Danchin. A double epidemic model for the SARS propagation. *BMC Infectious Diseases*, 3(1):19, September 2003.
- [10] Naeem Faraz, Yasir Khan, E. F. Doungmo Goufo, Amna Anjum, and Ali Anjum. Dynamic analysis of the mathematical model of COVID-19 with demographic effects. *Zeitschrift für Naturforschung C*, 75(11-12):389–396, 2020.

- [11] Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, Filip Machaj, Bartosz Szostak, Jarosław Przybyciński, Shahrokh Lorzadeh, Katarzyna Kotfis, Saeid Ghavami, and Marek J. Los. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. *Drug Resistance Updates*, page 100794, December 2021.
- [12] Jiaye Liu, Xuejiao Liao, Shen Qian, Jing Yuan, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Fu-Sheng Wang, Lei Liu, and Zheng Zhang. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. *Emerging Infectious Disease journal*, 26(6):1320, 2020.
- [13] Antoine Danchin and Gabriel Turinici. Immunity after COVID-19: Protection or sensitization? *Mathematical Biosciences*, 331:108499, 2021.
- [14] Dolbeault, Jean and Turinici, Gabriel. Heterogeneous social interactions and the COVID-19 lockdown outcome in a multi-group SEIR model. *Math. Model. Nat. Phenom.*, 15:36, 2020.
- [15] Antoine Danchin, Tuen Wai Ng, and Gabriel Turinici. A new transmission route for the propagation of the sars-cov-2 coronavirus. *Biology*, 10(1), 2021.
- [16] Martin Nowak and Robert M. May. *Virus Dynamics: Mathematical Principles of Immunology and Virology*. Oxford University Press, Oxford, New York, November 2000.
- [17] Dominik Wodarz. *Killer cell dynamics: mathematical and computational approaches to immunology*, volume 32. Springer, New York, 2007. OCLC: 184908900.
- [18] Yoram Louzoun. The evolution of mathematical immunology. *Immunological Reviews*, 216(1):9–20, 2007.
- [19] Mario Castro, Grant Lythe, Carmen Molina-Paris, and Ruy M. Ribeiro. Mathematics in modern immunology. *Interface Focus*, 6(2):20150093, 2016.
- [20] Raluca Eftimie, Joseph J. Gillard, and Doreen A. Cantrell. Mathematical Models for Immunology: Current State of the Art and Future Research Directions. *Bulletin of Mathematical Biology*, 78(10):2091–2134, October 2016.
- [21] Jean-Baptiste André and Sylvain Gandon. Vaccination, within-host dynamics and virulence evolution. *Evolution*, 60(1):13–23, January 2006. Publisher: John Wiley & Sons, Ltd.
- [22] Kasia A. Pawelek, Daniel Dor, Jr., Cristian Salmeron, and Andreas Handel. Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages. *PLOS ONE*, 11(2):e0150568, February 2016. Publisher: Public Library of Science.

- [23] Francois-Xavier Lescure, Lila Bouadma, Duc Nguyen, Marion Parisey, Paul-Henri Wicky, Sylvie Behillil, Alexandre Gaymard, Maude Bouscambert-Duchamp, Flora Donati, Quentin Le Hingrat, Vincent Enouf, Nadhira Houhou-Fidouh, Martine Valette, Alexandra Mailles, Jean-Christophe Lucet, France Mentre, Xavier Duval, Diane Descamps, Denis Malvy, Jean-François Timsit, Bruno Lina, Sylvie van-der Werf, and Yazdan Yazdanpanah. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *The Lancet Infectious Diseases*, 20(6):697–706, June 2020. Publisher: Elsevier.
- [24] Andrea Padoan, Chiara Cosma, Laura Sciacovelli, Diego Faggian, and Mario Plebani. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. *Clinical Chemistry and Laboratory Medicine*, 58(7):1081–1088, 2020.
- [25] Lirong Zou, Feng Ruan, Mingxing Huang, Lijun Liang, Huitao Huang, Zhongsi Hong, Jianxiang Yu, Min Kang, Yingchao Song, Jinyu Xia, Qianfang Guo, Tie Song, Jianfeng He, Hui-Ling Yen, Malik Peiris, and Jie Wu. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine*, 382(12):1177–1179, March 2020. Publisher: Massachusetts Medical Society. eprint: <https://doi.org/10.1056/NEJMc2001737>.
- [26] Quan-Xin Long, Xiao-Jun Tang, Qiu-Lin Shi, Qin Li, Hai-Jun Deng, Jun Yuan, Jie-Li Hu, Wei Xu, Yong Zhang, Fa-Jin Lv, Kun Su, Fan Zhang, Jiang Gong, Bo Wu, Xia-Mao Liu, Jin-Jing Li, Jing-Fu Qiu, Juan Chen, and Ai-Long Huang. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine*, pages 1–5, June 2020. Publisher: Nature Publishing Group.
- [27] Jeffrey Seow, Carl Graham, Blair Merrick, Sam Acors, Kathryn J.A. Steel, Oliver Hemmings, Aoife O’Byrne, Neophytos Kouphou, Suzanne Pickering, Rui Galao, Gilberto Betancor, Harry D Wilson, Adrian W Signell, Helena Winstone, Claire Kerridge, Nigel Temperton, Luke Snell, Karen Binauthsing, Amelia Moore, Adrian Green, Lauren Martinez, Brielle Stokes, Johanna Honey, Alba Izquierdo-Barras, Gill Arbane, Amita Patel, Lorcan O’Connell, Geraldine O Hara, Eithne MacMahon, Sam Douthwaite, Gaia Nebbia, Rahul Batra, Rocio Martinez-Nunez, Jonathan D. Edgeworth, Stuart J.D. Neil, Michael H. Malim, and Katie Doores. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. preprint, *Infectious Diseases (except HIV/AIDS)*, July 2020.
- [28] Biao Tang, Yanni Xiao, Beate Sander, Manisha A. Kulkarni, null RADAM-LAC Research Team, and Jianhong Wu. Modelling the impact of antibody-dependent enhancement on disease severity of Zika virus and dengue virus sequential and co-infection. *Royal Society Open Science*, 7(4):191749, 2020. Publisher: Royal Society.

- [29] Ewen Callaway, Heidi Ledford, and Smriti Mallapaty. Six months of coronavirus: the mysteries scientists are still racing to solve. *Nature*, 583(7815):178–179, July 2020. Number: 7815 Publisher: Nature Publishing Group.
- [30] David Ellinghaus, Frauke Degenhardt, Luis Bujanda, Maria Buti, Agustin Albillos, Pietro Invernizzi, Javier Fernandez, Daniele Prati, Guido Baselli, Rosanna Asselta, Marit Maehle Grimsrud, Chiara Milani, Fatima Aziz, Jan Kassens, Sandra May, Mareike Wendorff, Lars Wienbrandt, Florian Uellendahl-Werth, Tenghao Zheng, Xiaoli Yi, Raul de Pablo, Adolfo Garrido Chercoles, Adriana Palom, Alba-Estela Garcia-Fernandez, Francisco Rodriguez-Frias, Alberto Zanella, Alessandra Bandera, Alessandro Protti, Alessio Aghemo, Ana Lleo de Nalda, Andrea Biondi, Andrea Caballero-Garralda, Andrea Gori, Anja Tanck, Anna Latiano, Anna Ludovica Francanzani, Anna Peschuck, Antonio Julia, Antonio Pesenti, Antonio Voza, David Jimenez, Beatriz Mateos, Beatriz Nafria Jimenez, Carmen Quereda, Claudio Angelini, Cristina Cea, Aurora Solier, David Pestana, Elena Sandoval, Elvezia Maria Paraboschi, Enrique Navas, Ferruccio Ceriotti, Filippo Martinelli-Boneschi, Flora Peyvandi, Francesco Blasi, Luis Tellez, Albert Blanco-Grau, Giacomo Grasselli, Giorgio Costantino, Giulia Cardamone, Giuseppe Foti, Serena Aneli, Hayato Kurihara, Hesham ElAbd, Ilaria My, Javier Martin, Jeanette Erdmann, Jose Ferrusquia-Acosta, Koldo Garcia-Etxebarria, Laura Izquierdo-Sanchez, Laura Rachele Bettini, Leonardo Terranova, Leticia Moreira, Luigi Santoro, Luigia Scudeller, Francisco Mesonero, Luisa Roade, Marco Schaefer, Maria Carrabba, Maria del Mar Riveiro Barciela, Maria Eloina Figuera Basso, Maria Grazia Valsecchi, Maria Hernandez-Tejero, Marialbert Acosta-Herrera, Mariella D’Angio, Marina Baldini, Marina Cazzaniga, Martin Schulzky, Maurizio Cecconi, Michael Wittig, Michele Ciccarelli, Miguel Rodriguez-Gandia, Monica Bocciolone, Monica Miozzo, Nicole Braun, Nilda Martinez, Orazio Palmieri, Paola Faverio, Paoletta Preatoni, Paolo Bonfanti, Paolo Omodei, Paolo Tentorio, Pedro Castro, Pedro M. Rodrigues, Aaron Blandino Ortiz, Ricardo Ferrer Roca, Roberta Gualtierotti, Rosa Nieto, Salvatore Badalamenti, Sara Marsal, Giuseppe Matullo, Serena Pelusi, Valter Monzani, Tanja Wesse, Tomas Pumarola, Valeria Rimoldi, Silvano Bosari, Wolfgang Albrecht, Wolfgang Peter, Manuel Romero Gomez, Mauro D’Amato, Stefano Duga, Jesus M. Banales, Johannes Roksund Hov, Trine Folseraas, Luca Valenti, Andre Franke, and Tom Hemming Karlsen. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. *medRxiv*, page 2020.05.31.20114991, June 2020. Publisher: Cold Spring Harbor Laboratory Press.
- [31] Quan-Xin Long, Bai-Zhong Liu, Hai-Jun Deng, Gui-Cheng Wu, Kun Deng, Yao-Kai Chen, Pu Liao, Jing-Fu Qiu, Yong Lin, Xue-Fei Cai, De-Qiang Wang, Yuan Hu, Ji-Hua Ren, Ni Tang, Yin-Yin Xu, Li-Hua Yu, Zhan Mo, Fang Gong, Xiao-Li Zhang, Wen-Guang Tian, Li Hu, Xian-Xiang Zhang,

- Jiang-Lin Xiang, Hong-Xin Du, Hua-Wen Liu, Chun-Hui Lang, Xiao-He Luo, Shao-Bo Wu, Xiao-Ping Cui, Zheng Zhou, Man-Man Zhu, Jing Wang, Cheng-Jun Xue, Xiao-Feng Li, Li Wang, Zhi-Jie Li, Kun Wang, Chang-Chun Niu, Qing-Jun Yang, Xiao-Jun Tang, Yong Zhang, Xia-Mao Liu, Jin-Jing Li, De-Chun Zhang, Fan Zhang, Ping Liu, Jun Yuan, Qin Li, Jie-Li Hu, Juan Chen, and Ai-Long Huang. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine*, 26(6):845–848, June 2020. Number: 6 Publisher: Nature Publishing Group.
- [32] Kelvin Kai-Wang To, Owen Tak-Yin Tsang, Wai-Shing Leung, Anthony Raymond Tam, Tak-Chiu Wu, David Christopher Lung, Cyril Chik-Yan Yip, Jian-Piao Cai, Jacky Man-Chun Chan, Thomas Shiu-Hong Chik, Daphne Pui-Ling Lau, Chris Yau-Chung Choi, Lin-Lei Chen, Wan-Mui Chan, Kwok-Hung Chan, Jonathan Daniel Ip, Anthony Chin-Ki Ng, Rosana Wing-Shan Poon, Cui-Ting Luo, Vincent Chi-Chung Cheng, Jasper Fuk-Woo Chan, Ivan Fan-Ngai Hung, Zhiwei Chen, Honglin Chen, and Kwok-Yung Yuen. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*, 20(5):565–574, May 2020.
- [33] Jeffrey Seow, Carl Graham, Blair Merrick, Sam Acors, Kathryn J. A. Steel, Oliver Hemmings, Aoife O’Byrne, Neophytos Kouphou, Suzanne Pickering, Rui Galao, Gilberto Betancor, Harry D. Wilson, Adrian W. Signell, Helena Winstone, Claire Kerridge, Nigel Temperton, Luke Snell, Karen Binauthsing, Amelia Moore, Adrian Green, Lauren Martinez, Brielle Stokes, Johanna Honey, Alba Izquierdo-Barras, Gill Arbane, Amita Patel, Lorcan O’Connell, Geraldine O. Hara, Eithne MacMahon, Sam Douthwaite, Gaia Nebbia, Rahul Batra, Rocío Martínez-Núñez, Jonathan D. Edgeworth, Stuart J. D. Neil, Michael H. Malim, and Katie Doores. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv*, page 2020.07.09.20148429, July 2020. Publisher: Cold Spring Harbor Laboratory Press.
- [34] Moderna. Clinical study protocol. Online resource, August 2020. <https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf> Accessed: 2010-10-19.
- [35] Laura DeFrancesco. Whither COVID-19 vaccines? *Nature Biotechnology*, 38(10):1132–1145, October 2020.
- [36] Wen Shi Lee, Adam K. Wheatley, Stephen J. Kent, and Brandon J. DeKosky. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nature Microbiology*, 5(10):1185–1191, October 2020.
- [37] Gregory A. Poland, Inna G. Ovsyannikova, and Richard B. Kennedy. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. *The Lancet*, 0(0), October 2020. Publisher: Elsevier.

- [38] Qidi Wang, Lianfeng Zhang, Kazuhiko Kuwahara, Li Li, Zijie Liu, Taisheng Li, Hua Zhu, Jiangning Liu, Yanfeng Xu, Jing Xie, Hiroshi Morioka, Nobuo Sakaguchi, Chuan Qin, and Gang Liu. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. *ACS infectious diseases*, 2(5):361–376, 2016.
- [39] Sheng-Fan Wang, Sung-Pin Tseng, Chia-Hung Yen, Jyh-Yuan Yang, Ching-Han Tsao, Chun-Wei Shen, Kuan-Hsuan Chen, Fu-Tong Liu, Wu-Tse Liu, Yi-Ming Arthur Chen, and Jason C. Huang. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochemical and Biophysical Research Communications*, 451(2):208–214, August 2014.
- [40] Juanjuan Zhao, Quan Yuan, Haiyan Wang, Wei Liu, Xuejiao Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jinxiu Li, Shen Qian, Congming Hong, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Qing He, Zhiyong Li, Bin He, Tianying Zhang, Yang Fu, Shengxiang Ge, Lei Liu, Jun Zhang, Ningshao Xia, and Zheng Zhang. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clinical Infectious Diseases*, 2020.
- [41] Wenting Tan, Yanqiu Lu, Juan Zhang, Jing Wang, Yunjie Dan, Zhaoxia Tan, Xiaoqing He, Chunfang Qian, Qiangzhong Sun, Qingli Hu, Honglan Liu, Sikuan Ye, Xiaomei Xiang, Yi Zhou, Wei Zhang, Yanzhi Guo, Xiu-Hua Wang, Weiwei He, Xing Wan, Fengming Sun, Quanfang Wei, Cong Chen, Guangqiang Pan, Jie Xia, Qing Mao, Yaokai Chen, and Guohong Deng. Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv*, page 2020.03.24.20042382, March 2020. Publisher: Cold Spring Harbor Laboratory Press.
- [42] Baoqing Sun, Ying Feng, Xiaoneng Mo, Peiyan Zheng, Qian Wang, Pingchao Li, Ping Peng, Xiaoqing Liu, Zhilong Chen, Huimin Huang, Fan Zhang, Wenting Luo, Xuefeng Niu, Peiyu Hu, Longyu Wang, Hui Peng, Zhifeng Huang, Liqiang Feng, Feng Li, Fuchun Zhang, Fang Li, Nanshan Zhong, and Ling Chen. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. *Emerging Microbes & Infections*, 9(1):940–948, January 2020.
- [43] Mehul S Suthar, Matthew Zimmerman, Robert Kauffman, Grace Mantus, Susanne Linderman, Abigail Vanderheiden, Lindsay Nyhoff, Carl Davis, Seyi Adekunle, Maurizio Affer, Melanie Sherman, Stacian Reynolds, Hans Verkerke, David N Alter, Jeannette Guarner, Janetta Bryksin, Michael Horwath, Connie Arthur, Natia Saakadze, Geoffrey Hughes Smith, Srilatha Edupuganti, Erin M Scherer, Kieffer Hellmeister, Andrew Cheng, Juliet A Morales, Andrew S Neish, Sean R Stowell, Philipp Frank, Eric Ortlund, Evan Anderson, Vineet Menachery, Nadine Roupheal, Aneesh Metha, David S

- Stephens, Rafi Ahmed, John Roback, and Jens Wrämmert. Rapid generation of neutralizing antibody responses in COVID-19 patients. *medRxiv*, May 2020.
- [44] Abishek Chandrashekar, Jinyan Liu, Amanda J. Martinot, Katherine McMahan, Noe B. Mercado, Lauren Peter, Lisa H. Tostanoski, Jingyou Yu, Zoltan Maliga, Michael Nekorchuk, Kathleen Busman-Sahay, Margaret Terry, Linda M. Wrijil, Sarah Ducat, David R. Martinez, Caroline Atyeo, Stephanie Fischinger, John S. Burke, Matthew D. Slein, Laurent Pessaint, Alex Van Ry, Jack Greenhouse, Tammy Taylor, Kelvin Blade, Anthony Cook, Brad Finneyfrock, Renita Brown, Elyse Teow, Jason Velasco, Roland Zahn, Frank Wegmann, Peter Abbink, Esther A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Xuan He, Catherine Jacob-Dolan, Nicole Kordana, Zhenfeng Li, Michelle A. Lifton, Shant H. Mahrokhian, Lori F. Maxfield, Ramya Nityanandam, Joseph P. Nkolola, Aaron G. Schmidt, Andrew D. Miller, Ralph S. Baric, Galit Alter, Peter K. Sorger, Jacob D. Estes, Hanne Andersen, Mark G. Lewis, and Dan H. Barouch. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*, May 2020. Publisher: American Association for the Advancement of Science Section: Research Article.
- [45] Fan Wu, Aojie Wang, Mei Liu, Qimin Wang, Jun Chen, Shuai Xia, Yun Ling, Yuling Zhang, Jingna Xun, Lu Lu, Shibo Jiang, Hongzhou Lu, Yumei Wen, and Jinghe Huang. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv*, page 2020.03.30.20047365, April 2020. Publisher: Cold Spring Harbor Laboratory Press.
- [46] Derek Larson, Sterling L Brodniak, Logan J Voegtly, Regina Z Cer, Lindsay A Glang, Francisco J Malagon, Kyle A Long, Ronald Potocki, Darci R Smith, Charlotte Lanteri, Timothy Burgess, and Kimberly A Bishop-Lilly. A Case of Early Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical Infectious Diseases*, 73(9):e2827–e2828, November 2021.
- [47] Centers for Disease Control and Prevention (CDC). HAN Archive - 00432 | Health Alert Network (HAN), May 2020. <https://emergency.cdc.gov/han/2020/han00432.asp>.
- [48] Katherine Harmon Courage. What we know about the new Covid-19-linked illness in children, May 2020. Library Catalog: www.vox.com, <https://www.vox.com/2020/5/13/21257568/kids-covid-19-kawasaki-pediatric-multisymptom-inflammatory-disease>.
- [49] Lucio Verdoni, Angelo Mazza, Annalisa Gervasoni, Laura Martelli, Maurizio Ruggeri, Matteo Ciuffreda, Ezio Bonanomi, and Lorenzo D’Antiga. An outbreak of severe Kawasaki-like disease at the Italian epicentre of

- the SARS-CoV-2 epidemic: an observational cohort study. *The Lancet*, 395(10239):1771–1778, June 2020. Publisher: Elsevier.
- [50] Shelley Riphagen, Xabier Gomez, Carmen Gonzalez-Martinez, Nick Wilkinson, and Paraskevi Theocharis. Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*, 395(10237):1607–1608, May 2020. Publisher: Elsevier.
- [51] Russell M. Viner and Elizabeth Whittaker. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *The Lancet*, 395(10239):1741–1743, June 2020. Publisher: Elsevier.
- [52] Camila Rosat Consiglio, Nicola Cotugno, Fabian Sardh, Christian Pou, Donato Amodio, Lucie Rodriguez, Ziyang Tan, Sonia Zicari, Alessandra Ruggiero, Giuseppe Rubens Pascucci, Veronica Santilli, Tessa Campbell, Yenan Bryceson, Daniel Eriksson, Jun Wang, Alessandra Marchesi, Tadeppally Lakshmikanth, Andrea Campana, Alberto Villani, Paolo Rossi, Nils Landegren, Paolo Palma, and Petter Brodin. The Immunology of Multi-system Inflammatory Syndrome in Children with COVID-19. *Cell*, 0(0), September 2020. Publisher: Elsevier.
- [53] Ha Youn Lee, David J. Topham, Sung Yong Park, Joseph Hollenbaugh, John Treanor, Tim R. Mosmann, Xia Jin, Brian M. Ward, Hongyu Miao, Jeanne Holden-Wiltse, Alan S. Perelson, Martin Zand, and Hulin Wu. Simulation and prediction of the adaptive immune response to influenza A virus infection. *Journal of Virology*, 83(14):7151–7165, July 2009.
- [54] Chentong Li, Jinhu Xu, Jiawei Liu, and Yicang Zhou. The within-host viral kinetics of SARS-CoV-2. *Mathematical Biosciences and Engineering*, 17(4):2853, 2020. Company: Aims Press Distributor: Aims Press Institution: Aims Press Label: Aims Press Publisher: AIMS Press.
- [55] Alan S. Perelson, Denise E. Kirschner, and Rob De Boer. Dynamics of HIV infection of CD4+ T cells. *Mathematical Biosciences*, 114(1):81–125, March 1993.
- [56] Hal L. Smith and Patrick De Leenheer. Virus Dynamics: A Global Analysis. *SIAM Journal on Applied Mathematics*, 63(4):1313–1327, January 2003. Publisher: Society for Industrial and Applied Mathematics.
- [57] Edward John Routh. *A Treatise on the Stability of a Given State of Motion, Particularly Steady Motion: Being the Essay to which the Adams Prize was Adjudged in 1877, in the University of Cambridge*. Macmillan and Company, 1877.
- [58] I. S. Gradshteyn and I. M. Ryzhik. *Table of integrals, series, and products. Translated from the Russian. Translation edited and with a preface by Alan Jeffrey and Daniel Zwillinger*. San Diego, CA: Academic Press, 2000.

A Additional motivations

A.1 Available evidence detailing the antibody response

For clinical reasons and also for the understanding of those studying vaccines, antibody responses are of paramount importance; SARS-CoV-2 specific antibodies are usually detected during the second week after illness onset (see [31, 32]) and remain active thereafter for an unknown time span (see however [33] for recent information). Antibody responses are mainly directed against the RBD-spike and nucleocapsid proteins. However, the neutralization capacities of these specific antibodies is still under discussion, especially since weak or non-neutralizing antibodies can enhance infection through a process called antibody-dependent enhancement (hereafter abbreviated 'ADE') [2, 3, 4, 5]. This has been recently emphasized in the set up of clinical trials (see for example [34]), in a general discussion of the prospects of vaccination [35] and in a perspective accounting for the present situation in terms of SARS-CoV-2 vaccines, therapies and immunity [36, 37]

The present academic interpretation of the ADE is that it occurs through virus-antibody immunocomplexes that facilitate virus internalization in host cells that do not express virus receptor but Fc receptors. ADE is induced when the antibody-virus stoichiometry is below the threshold for neutralization, [2, 3]. As a consequence, neutralizing antibodies may enhance infection when their concentrations fall below a key occupancy threshold, and some poorly neutralizing antibodies may strongly increase infection over a wide dose-response range. ADE has been demonstrated in vitro for many viral infections, including that triggered by SARS-CoV-1 which was reported to infect in vitro human macrophages (see [4]) and human B cell lines via an ADE pathway, (see [5]). Moreover, Qidi Wang et al. reported that a specific spike protein epitope elicited antibodies which could enhance infection via ADE, while other epitopes induced neutralizing antibodies in non-human primates. Furthermore, the authors showed that a SARS-CoV-1 inactivated vaccine could induce ADE and lung pathology in experimental rhesus monkeys [38]. In contrast, Martial Jaume and co-authors showed that vaccine candidates which mediated in vitro ADE infection could still be neutralizing and protective in vivo on rhesus macaques, [5]. Moreover, in most cases, ADE infected cells do not support viral replication, [4, 5]. Instead, ADE may trigger cell apoptosis and promote tissue inflammation and injury with the release of pro-inflammatory cytokines from infected cells, [3, 39]. As a result, whether ADE actually happens in SARS-CoV-1 infected humans and is a factor of disease severity is still a debated research subject since no in vivo human evidence has been demonstrated yet (but this statement is very time-dependent given the present intense research on SARS-CoV-2). Note however, that SARS-CoV-1 infected patients who developed a higher and earlier antibody response were associated with worse clinical outcome. An early antibody response may be weakly neutralizing compared to a later one. As a consequence, a high concentration of those antibodies could lead to ADE and enhancement of infection.

The question of ADE and the link between antibody dynamics and disease evolution is still unclear for COVID-19. J. Zhao et al. reported a strong positive correlation between disease severity and high antibody titers two weeks after illness onset. The antibody level is considered as a risk factor for severe evolution, independently from age, gender and comorbidities [40]. In another study, Wenting Tan et al also came to the same conclusion: higher titers of anti-N IgM and anti-N IgG are observed for severe patients [41]. Finally, Baoqing Sun et al observed that severe patients had higher levels N-IgG than S-IgG after the symptoms onset. However, according to the authors, whether N-specific antibodies can block virus infection is still open to question [42]. The secretion of a high level of weakly neutralizing antibody supports the hypothesis of ADE for COVID-19 which can partially explain some clinical complications. In contrast, Mehul S. Suthar et al concluded that the appearance of high titer neutralizing antibody responses early after the infection was promising and may offer some degree of protection against re-infection [43]. This result seems to be confirmed in a recent study in which SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates. However, rhesus macaques do not develop severe clinical complications as reported in human patients, suggesting that if rhesus macaques produce neutralizing antibodies, transposition of this observation to humans is still to be investigated [44]. Finally, a recent study on a recovered cohort of COVID-19 patients showed that elderly patients had significantly higher levels of antibodies than younger patients. However, severe and critical patients were excluded from the study because they received passive antibody treatment before sample collection. As a result, the authors could not directly evaluate the effect of antibodies on virus clearance or disease progression in COVID-19 patients [45]. This suggests that if elderly patients tend to develop higher titers of antibodies, those may not be systematically associated with worse clinical evolution. What should rather be answered is whether disease severity is systematically associated with high antibody levels.

On the other hand, the vaccine community is increasingly aware of this need (see discussion on ADE in [36, 35, 37]) and studies along these lines are required.

Another motivation comes from the fact that the adaptive immune system response starts in about a week; on the other hand in many mild forms infection is resolved in around a week while on the contrary severe forms may at first start as mild and only then become severe; a simplistic view may indicate that the innate immune response is very efficient while the adaptive immune system response may be detrimental. In this case, everyone with a mild first infection (i.e., mostly dealt with by the innate immune system) will, upon re-infection, see an adaptive immune response rising faster (once the memory is in place, its response is faster than the innate immune response) and thus the detrimental effects could be visible for people previously having experienced mild forms, e.g., low age class individuals.

A.2 Evidence on re-infection

The possible unfavorable outcomes of a secondary infection (challenge) following a primary SARS-CoV-2 infection were described in various situations (see for example [46]), but an increasing body of evidence highlights the Kawasaki-like syndrome as a possible negative outcome, see [47, 48, 49, 50, 51].

An Italian study [49] indicates that the immune response to SARS-CoV-2 is responsible for the appearance of a pediatric Kawasaki-like syndrome (Kawasaki-like disease or Multisystem Inflammatory Syndrome in Children MIS-C in the US). In this study, 8 to 10 children have been tested positive to IgG, IgM or both (the infection to SARS-CoV-2 preceded the development of the syndrome) and 2 only in PCR (the infection was simultaneous). SARS-CoV-2 infected children who developed the Kawasaki-like syndrome (KLS) were on average older and more severely hit than other children victims of the classical Kawasaki syndrome.

The same phenomena has been observed in the US and UK [47, 50, 51]. Academic studies begin to investigate the interplay between COVID-19 and the MIS-C [52].

The causes of the development of the Kawasaki disease are still unknown. The best accepted hypothesis is that of an abnormal immune response that occurs as a result of the infection provoked by one of several pathogenic agents for the genetically susceptible patients. The triggering pathogens have not yet been identified.

To account for the peaks of the KLS cases following an infection with SARS-CoV-2, two hypotheses may be formulated: the antibodies produced by the children can induce the initiation of an autoimmune disease and syndromes similar to the Kawasaki syndrome. The second hypothesis is an ADE-type mechanism.

B Choice of simulation parameters

Parameters' order of magnitude were derived from literature, see [53] for μ , [23] for ω , clearance data from [28, 54, 26, 27]. To obtain the precise values, we then fitted the model to the SARS-CoV-2 clinical data available in figure 2 and obtained the values in table 1 (simulation results are shown in figure 3).

C Sensitivity with respect to parameters

We plot here a longer time evolution corresponding to figures 4 and 5. This allows to see the difference between initial dynamics and the long time equilibrium, cf. considerations in section 3.3.




Figure 6: Simulation in figure 4 for a longer time span.




Figure 7: Simulation in 5 for a longer time span.

D Mathematical properties of the model

We describe in an incremental way the mathematical properties of the main model (1)-(5). We take advantage of this description to illustrate the hypotheses (6) and (7). The results in sections D.1 and D.3 are known, see e.g., [55, 16, 56, 17] while those in the main text (propositions 1, 2 and their proofs in this appendix) are, to the best of our knowledge, original.

D.1 Model without a virus, nor immune response

In absence of any infection the equations for the target cells are (see [17, 16]):

$$dT/dt = \Lambda - \mu T. \quad (16)$$

Since the Jacobian matrix at equilibrium (a 1×1 matrix) is the constant $-\mu$ therefore the equilibrium is stable, in fact any initial data $T(0)$ will converge to the equilibrium

$$T^* = \Lambda/\mu. \quad (17)$$

D.2 Model with virus but no immune response

We employ the basic model of virus dynamics, see [16, eq (3.1) page 18] and also [17, eqns. (2.3)-(2.4) page 26] described by the equations:

$$dT/dt = \Lambda - \mu T - \beta_0 VT, \quad (18)$$

$$dI/dt = \beta_0 VT - \delta I, \quad (19)$$

$$dV/dt = \omega I - cV. \quad (20)$$

The initial conditions are:

$$T(0) = T^* = \Lambda/\mu, \quad I(0) = 0, \quad V(0) > 0, \quad (21)$$

which express the fact that the initial state for T is the stable equilibrium seen in section D.1, there are initially no infected cells and the initial viral load is strictly positive.

It is natural to assume that the decay rate of infected cells is at least as large as the decay rate of healthy cells, i.e., assumption (6).

In this model, an infection is only possible if the basic reproduction ratio of the virus in the absence of immune response, defined in (8) is strictly super-unitary, that is

$$R_0 > 1. \quad (22)$$

Otherwise, that is if $R_0 \leq 1$, the initial viral load can only decrease. The model has two equilibria:

- trivial equilibrium: $T = T^* = \Lambda/\mu$, $V = I = 0$. The Jacobian matrix at equilibrium is $\begin{pmatrix} -\mu & 0 & -\beta_0 T^* \\ 0 & -\delta & \beta_0 T^* \\ 0 & \omega & -c \end{pmatrix}$. The eigenvalues of this matrix, under

condition (22), are all real but not all negative: one of them is $\lambda_1 = -\mu$ but the product of the other two is $\delta c - \omega\beta_0 T^* \leq 0$ thus at least one is positive. Therefore, under assumption (22), this critical point is not a stable equilibrium.

- the "immunosuppression" equilibrium (11)

The Jacobian matrix is $\begin{pmatrix} -\mu - \beta_0 V^{is} & 0 & -\beta_0 T^{is} \\ \beta_0 V^{is} & -\delta & \beta_0 T^{is} \\ 0 & \omega & -c \end{pmatrix}$; the characteristic

polynomial $P(X) = (X + \delta)(X + c)(X + \mu + \beta_0 V^{is}) - \delta c(X + \mu)$ has the following properties: $P(-\infty) < 0$, $P(-\delta - c) = \delta c \beta_0 V^{is} > 0$, thus it has a real root which is smaller than $-\delta - c$. The product of all roots is $\delta c \beta_0 V^{is} > 0$ and the sum of all roots is $-\delta - c - \mu - \beta_0 V^{is} < -\delta - c$, thus the other two roots have negative real part. Therefore the equilibrium is stable.

It is important to note that the viral load V^{is} is the viral load that the infection will cause in a completely immunodeficient individual. We expect V^{is} to be significantly high, see in section D.3 for details.

D.3 Model: virus and immune response but no enhancement

In this section we consider the model (1)-(4) with no ADE i.e., $\beta(A) = \beta_0$ that is $\beta_1 = 0$. This model is similar to other in the literature (see for instance [17, eq. (2.9) page 29] who consider also the cytotoxic effect of the immune response on the infected cells; however they do not consider virus destruction by antibodies. In particular there virus load is constant. Another similar model is [17, eqns. (8.1)-(8.3)]. With respect to the previous section here the immune response is present. It is triggered by a threshold set at V^t (see definition in (9)). It is natural to suppose that the immune response threshold is a very small value and in any case a value smaller than the immunosuppression viral load V^{is} in (11). That is we can make the hypothesis that $V^{is} > V^t$ i.e. assumption (7) holds.

The Jacobian matrix is:

$$J = \begin{pmatrix} -(\mu + \beta_0 V^{is}) & 0 & -\beta_0 T & 0 \\ \beta_0 V & -\delta & \beta_0 T & 0 \\ 0 & \omega & -(c + bA) & -bV \\ 0 & 0 & aA & aV - \sigma \end{pmatrix}. \quad (23)$$

With these provisions, one can find analytically the critical points (equilibria candidates):

1. $T = T^* = \Lambda/\mu$, $V = I = A = 0$, which is the high dimensional analog of equilibrium (17). However, unlike in section D.1, this equilibrium is not stable any more (the determinant of the Jacobian matrix is negative when hypothesis (22) is satisfied).
2. the immunosuppression equilibrium (11) with $A = 0$; again this equilibrium is not stable any more because the condition (7) implies that the eigenvalue $aV^{is} - \sigma$ is positive.

3. the only critical point left is (10) We prove that it is stable in the following.
Note that the equilibrium value of the antibody level is positive due to condition (7).

Proof of the Proposition 1. The equilibrium is stable when the real parts of the eigenvalues of the Jacobian matrix are negative. This is the same as saying that the roots of the polynomials $P_0(X) = \det(X \cdot I - J)$ have negative real parts (here I is the identity matrix). Such a polynomial is called stable and, if we write $P_0(X) = \gamma_4 X^4 + \gamma_3 X^3 + \gamma_2 X^2 + \gamma_1 X^1 + \gamma_0$ then, following the Routh-Hurwitz criterion [57], [58, p. 1076], the stability holds true when

$$\gamma_k > 0, k = 0, 1, 2, 3, 4 \quad (24)$$

and

$$\gamma_1 \gamma_2 \gamma_3 > \gamma_4 \gamma_1^2 + \gamma_3^2 \gamma_0. \quad (25)$$

Unfortunately, checking in general these conditions is very difficult because the expressions involved are highly non-linear in the original parameters of the model (a, b, c, σ , etc.). We therefore need to exploit to the full extent the specific setting of our model. To this end we will make the following change of variables:

$$\zeta = \delta - \mu > 0, \quad w = R_0 - 1 - \frac{\sigma \beta_0}{\mu a} > 0. \quad (26)$$

After replacing all new variables and direct computations, we obtain:

$$\begin{aligned} \gamma_0 &= c \delta \mu \sigma w, \quad \gamma_1 = \frac{c \sigma (a^2 \delta \mu w + a^2 \mu^2 w + a \beta_0 \delta \mu w + a \beta_0 \delta \mu + a \beta_0 \mu \sigma w + \beta_0^2 \delta \sigma)}{a(a\mu + \beta_0 \sigma)}, \\ \gamma_2 &= \frac{a^2 c \mu^2 w + a^2 c \mu^2 + a^2 c \mu \sigma w + a^2 \delta \mu^2 + a \beta_0 c \mu \sigma w + 2a \beta_0 c \mu \sigma + 2a \beta_0 \delta \mu \sigma + \beta_0^2 c \sigma^2 + \beta_0^2 \delta \sigma^2}{a(a\mu + \beta_0 \sigma)}, \\ \gamma_3 &= \frac{a^2 \delta \mu + a^2 \mu^2 + a \beta_0 \delta \sigma + 2a \beta_0 \mu \sigma + a c (\mu(w+1) + \beta_0 \sigma) + \beta_0^2 \sigma^2}{a(a\mu + \beta_0 \sigma)}, \quad \gamma_4 = 1. \end{aligned}$$

Since all parameters involved are positive we obtain that the condition (24) is satisfied. To check the remaining condition (25) we obtain

$$\gamma_1 \gamma_2 \gamma_3 - \gamma_4 \gamma_1^2 + \gamma_3^2 \gamma_0 = \frac{ac}{a^3 (a\mu + \beta_0 \sigma)^3} Q_0(w, a, c, \beta_0, \mu, \sigma, \zeta), \quad (27)$$

where the multi-variable polynomial Q_0 is seen, after long but straightforward computations, to be equal to :

$$\begin{aligned} Q_0(w, a, c, \beta_0, \mu, \sigma, \zeta) &= w^3 a^6 c^2 \mu^5 + 2w^3 a^6 c^2 \mu^4 \sigma + w^3 a^6 c^2 \mu^3 \sigma \zeta + w^3 a^5 c^2 \beta_0 \mu^5 + \\ &+ 3w^3 a^5 c^2 \beta_0 \mu^4 \sigma + w^3 a^5 c^2 \beta_0 \mu^4 \zeta + w^3 a^5 c^2 \beta_0 \mu^3 \sigma^2 + w^3 a^5 c^2 \beta_0 \mu^3 \sigma \zeta + w^3 a^4 c^2 \beta_0^2 \mu^4 \sigma + \\ &+ w^3 a^4 c^2 \beta_0^2 \mu^3 \sigma^2 + w^3 a^4 c^2 \beta_0^2 \mu^3 \sigma \zeta + 2w^2 a^6 c^2 \mu^5 + 2w^2 a^6 c^2 \mu^4 \sigma + w^2 a^6 c^2 \mu^3 \sigma \zeta + \\ &+ 2w^2 a^6 c \mu^6 + w^2 a^6 c \mu^5 \zeta + 3w^2 a^5 c^2 \beta_0 \mu^5 + 8w^2 a^5 c^2 \beta_0 \mu^4 \sigma + 3w^2 a^5 c^2 \beta_0 \mu^4 \zeta + 3w^2 a^5 c^2 \beta_0 \mu^3 \sigma^2 + \\ &+ 2w^2 a^5 c^2 \beta_0 \mu^3 \sigma \zeta + w^2 a^5 c^2 \beta_0 \mu^2 \sigma^2 \zeta + 3w^2 a^5 c \beta_0 \mu^6 + 5w^2 a^5 c \beta_0 \mu^5 \sigma + 5w^2 a^5 c \beta_0 \mu^5 \zeta + \\ &+ 2w^2 a^5 c \beta_0 \mu^4 \zeta^2 - w^2 a^5 c \beta_0 \mu^3 \sigma \zeta^2 + 6w^2 a^4 c^2 \beta_0^2 \mu^4 \sigma + 8w^2 a^4 c^2 \beta_0^2 \mu^3 \sigma^2 + 6w^2 a^4 c^2 \beta_0^2 \mu^3 \sigma \zeta + \\ &+ w^2 a^4 c^2 \beta_0^2 \mu^2 \sigma^3 + 2w^2 a^4 c^2 \beta_0^2 \mu^2 \sigma^2 \zeta + 6w^2 a^4 c \beta_0^2 \mu^5 \sigma + 6w^2 a^4 c \beta_0^2 \mu^4 \sigma^2 + 9w^2 a^4 c \beta_0^2 \mu^4 \sigma \zeta - \\ &+ w^2 a^4 c \beta_0^2 \mu^3 \sigma^2 \zeta + 3w^2 a^4 c \beta_0^2 \mu^3 \sigma \zeta^2 - w^2 a^4 c \beta_0^2 \mu^2 \sigma^2 \zeta^2 + 3w^2 a^3 c^2 \beta_0^3 \mu^3 \sigma^2 + 2w^2 a^3 c^2 \beta_0^3 \mu^2 \sigma^3 + \\ &+ 3w^2 a^3 c^2 \beta_0^3 \mu^2 \sigma^2 \zeta + 4w^2 a^3 c \beta_0^3 \mu^4 \sigma^2 + 4w^2 a^3 c \beta_0^3 \mu^3 \sigma^3 + 5w^2 a^3 c \beta_0^3 \mu^3 \sigma^2 \zeta + w^2 a^3 c \beta_0^3 \mu^2 \sigma^2 \zeta^2 + \\ &+ w^2 a^2 c \beta_0^4 \mu^3 \sigma^3 + w^2 a^2 c \beta_0^4 \mu^2 \sigma^4 + w^2 a^2 c \beta_0^4 \mu^2 \sigma^3 \zeta + w a^6 c^2 \mu^5 + 2w a^6 c \mu^6 + w a^6 c \mu^5 \zeta + \\ &+ 3w a^5 c^2 \beta_0 \mu^5 + 5w a^5 c^2 \beta_0 \mu^4 \sigma + 3w a^5 c^2 \beta_0 \mu^4 \zeta + w a^5 c^2 \beta_0 \mu^3 \sigma \zeta + 6w a^5 c \beta_0 \mu^6 + 7w a^5 c \beta_0 \mu^5 \sigma + \end{aligned}$$

$$\begin{aligned}
& 10wa^5c\beta_0\mu^5\zeta + wa^5c\beta_0\mu^4\sigma\zeta + 4wa^5c\beta_0\mu^4\zeta^2 - wa^5c\beta_0\mu^3\sigma\zeta^2 + 2wa^5\beta_0\mu^7 + 5wa^5\beta_0\mu^6\zeta + \\
& 4wa^5\beta_0\mu^5\zeta^2 + wa^5\beta_0\mu^4\zeta^3 + 9wa^4c^2\beta_0^2\mu^4\sigma + 8wa^4c^2\beta_0^2\mu^3\sigma^2 + 9wa^4c^2\beta_0^2\mu^3\sigma\zeta + \\
& 2wa^4c^2\beta_0^2\mu^2\sigma^2\zeta + 18wa^4c\beta_0^2\mu^5\sigma + 11wa^4c\beta_0^2\mu^4\sigma^2 + 28wa^4c\beta_0^2\mu^4\sigma\zeta - wa^4c\beta_0^2\mu^3\sigma^2\zeta + \\
& 10wa^4c\beta_0^2\mu^3\sigma\zeta^2 - 2wa^4c\beta_0^2\mu^2\sigma^2\zeta^2 + 7wa^4\beta_0^2\mu^6\sigma + 17wa^4\beta_0^2\mu^5\sigma\zeta + 13wa^4\beta_0^2\mu^4\sigma\zeta^2 + \\
& 3wa^4\beta_0^2\mu^3\sigma\zeta^3 + 9wa^3c^2\beta_0^3\mu^3\sigma^2 + 5wa^3c^2\beta_0^3\mu^2\sigma^3 + 9wa^3c^2\beta_0^3\mu^2\sigma^2\zeta + wa^3c^2\beta_0^3\mu\sigma^3\zeta + \\
& 20wa^3c\beta_0^3\mu^4\sigma^2 + 10wa^3c\beta_0^3\mu^3\sigma^3 + 28wa^3c\beta_0^3\mu^3\sigma^2\zeta - wa^3c\beta_0^3\mu^2\sigma^3\zeta + 8wa^3c\beta_0^3\mu^2\sigma^2\zeta^2 - \\
& wa^3c\beta_0^3\mu\sigma^3\zeta^2 + 9wa^3\beta_0^3\mu^5\sigma^2 + 21wa^3\beta_0^3\mu^4\sigma^2\zeta + 15wa^3\beta_0^3\mu^3\sigma^2\zeta^2 + 3wa^3\beta_0^3\mu^2\sigma^2\zeta^3 + \\
& 3wa^2c^2\beta_0^4\mu^2\sigma^3 + wa^2c^2\beta_0^4\mu\sigma^4 + 3wa^2c^2\beta_0^4\mu\sigma^3\zeta + 10wa^2c\beta_0^4\mu^3\sigma^3 + 5wa^2c\beta_0^4\mu^2\sigma^4 + \\
& 12wa^2c\beta_0^4\mu^2\sigma^3\zeta + 2wa^2c\beta_0^4\mu\sigma^3\zeta^2 + 5wa^2\beta_0^4\mu^4\sigma^3 + 11wa^2\beta_0^4\mu^3\sigma^3\zeta + 7wa^2\beta_0^4\mu^2\sigma^3\zeta^2 + \\
& wa^2\beta_0^4\mu\sigma^3\zeta^3 + 2wac\beta_0^5\mu^2\sigma^4 + wac\beta_0^5\mu\sigma^5 + 2wac\beta_0^5\mu\sigma^4\zeta + wa\beta_0^5\mu^3\sigma^4 + 2wa\beta_0^5\mu^2\sigma^4\zeta + \\
& wa\beta_0^5\mu\sigma^4\zeta^2 + a^5c^2\beta_0\mu^5 + a^5c^2\beta_0\mu^4\zeta + 3a^5c\beta_0\mu^6 + 5a^5c\beta_0\mu^5\zeta + 2a^5c\beta_0\mu^4\zeta^2 + \\
& 2a^5\beta_0\mu^7 + 5a^5\beta_0\mu^6\zeta + 4a^5\beta_0\mu^5\zeta^2 + a^5\beta_0\mu^4\zeta^3 + 4a^4c^2\beta_0^2\mu^4\sigma + 4a^4c^2\beta_0^2\mu^3\sigma\zeta + \\
& 12a^4c\beta_0^2\mu^5\sigma + 19a^4c\beta_0^2\mu^4\sigma\zeta + 7a^4c\beta_0^2\mu^3\sigma\zeta^2 + 9a^4\beta_0^2\mu^6\sigma + 22a^4\beta_0^2\mu^5\sigma\zeta + 17a^4\beta_0^2\mu^4\sigma\zeta^2 + \\
& 4a^4\beta_0^2\mu^3\sigma\zeta^3 + 6a^3c^2\beta_0^3\mu^3\sigma^2 + 6a^3c^2\beta_0^3\mu^2\sigma^2\zeta + 19a^3c\beta_0^3\mu^4\sigma^2 + 28a^3c\beta_0^3\mu^3\sigma^2\zeta + \\
& 9a^3c\beta_0^3\mu^2\sigma^2\zeta^2 + 16a^3\beta_0^3\mu^5\sigma^2 + 38a^3\beta_0^3\mu^4\sigma^2\zeta + 28a^3\beta_0^3\mu^3\sigma^2\zeta^2 + 6a^3\beta_0^3\mu^2\sigma^2\zeta^3 + \\
& 4a^2c^2\beta_0^4\mu^2\sigma^3 + 4a^2c^2\beta_0^4\mu\sigma^3\zeta + 15a^2c\beta_0^4\mu^3\sigma^3 + 20a^2c\beta_0^4\mu^2\sigma^3\zeta + 5a^2c\beta_0^4\mu\sigma^3\zeta^2 + \\
& 14a^2\beta_0^4\mu^4\sigma^3 + 32a^2\beta_0^4\mu^3\sigma^3\zeta + 22a^2\beta_0^4\mu^2\sigma^3\zeta^2 + 4a^2\beta_0^4\mu\sigma^3\zeta^3 + ac^2\beta_0^5\mu\sigma^4 + ac^2\beta_0^5\sigma^4\zeta + \\
& 6ac\beta_0^5\mu^2\sigma^4 + 7ac\beta_0^5\mu\sigma^4\zeta + ac\beta_0^5\sigma^4\zeta^2 + 6a\beta_0^5\mu^3\sigma^4 + 13a\beta_0^5\mu^2\sigma^4\zeta + 8a\beta_0^5\mu\sigma^4\zeta^2 + \\
& a\beta_0^5\sigma^4\zeta^3 + c\beta_0^6\mu\sigma^5 + c\beta_0^6\sigma^5\zeta + \beta_0^6\mu^2\sigma^5 + 2\beta_0^6\mu\sigma^5\zeta + \beta_0^6\sigma^5\zeta^2.
\end{aligned}$$

Most of the monomials in Q_0 have positive coefficients, except the following ones: $-w^2a^5c\beta_0\mu^3\sigma\zeta^2$, $-w^2a^4c\beta_0^2\mu^3\sigma^2\zeta$, $-w^2a^4c\beta_0^2\mu^2\sigma^2\zeta^2$, $-wa^5c\beta_0\mu^3\sigma\zeta^2$, $-wa^4c\beta_0^2\mu^3\sigma^2\zeta$, $-2wa^4c\beta_0^2\mu^2\sigma^2\zeta^2$, $-wa^3c\beta_0^3\mu^2\sigma^3\zeta$, $-wa^3c\beta_0^3\mu\sigma^3\zeta^2$. However, in all cases we can come up with two terms that render the total sum positive. For instance the term $-w^2a^5c\beta_0\mu^3\sigma\zeta^2$ (term 27 of the polynomial) is negative but, when we combine it with the terms $w^3a^6c^2\mu^3\sigma\zeta/2$ (half of the third term) and $wa^4\beta_0^2\mu^3\sigma\zeta^3/2$ (half of the term 79), both appearing with positive coefficients, we obtain a positive number $w^3a^6c^2\mu^3\sigma\zeta/2 - w^2a^5c\beta_0\mu^3\sigma\zeta^2 + wa^4\beta_0^2\mu^3\sigma\zeta^3/2 = \frac{w\mu^3\sigma\zeta}{2}(wac - \beta_0\zeta)^2 \geq 0$.

The interested reader can check that in the same way that:

- the 36-th monomial compensate with monomials 7 and 92;
- the 38-th monomial compensate with monomials 3 and 104;
- the 61-th monomial compensate with monomials 14 and 128;
- the 73-th monomial compensate with monomials 13 and 145;
- the 75-th monomial compensate with monomials 14 and 146;
- the 87-th monomial compensate with monomials 20 and 154;
- the 89-th monomial compensate with monomials 22 and 155.

This allows to state that $Q_0 > 0$ which concludes the proof. \square

D.4 Full model: virus, immune system and ADE

Proof of the Proposition 2. We consider the model (1)-(4) with $\beta(A) = \beta_0 + \beta_1 A$ ($\beta_1 > 0$). The analysis of this dynamics is more involved. The first two equilibria, having $A = 0$ are the complete analogues of the equilibria seen in previous sections and have no dynamical interest. Since $A = 0$ the parameter β_1 that multiplies A has no impact and the proof of the instability of the trivial equi-

librium and immunosuppression equilibrium follow exactly the same arguments as before.

To find the third equilibrium, note that after immediate computations we find that the antibody level is solution of the second order equation (12). Such an equation has two solutions but exactly one is positive because the product of roots is negative; thus only a single point is an admissible equilibrium, namely the positive solution of (12) (with respect to the unknown A); setting to zero all derivatives we obtain the other values as in (13).

To prove the properties of this equilibrium we start with the point 3c of the proposition; consider the values $a = \sigma = c = b = \omega = 1$, $\mu = 1.e - 3$, $\delta = 2$, $\Lambda = 4$, $\beta_0 = 0.0011$ and $\beta_1 = 0.01188$; all hypotheses are satisfied and the numerical values of the equilibrium are $T = 333.33$, $I = 1.83$, $V = 1$, $A = 0.83$ while the eigenvalues are -3.45 , 0.50 , 0.01 and -0.90 . Since some eigenvalues are real and positive the equilibrium is not stable for this set of parameters. This completes the proof for this point. In practice the evolution oscillates indefinitely between a state with high T value and one with very low T value.

Note that the point 3a of the conclusion is just a consequence of the continuity and the proposition 1, because both the equilibrium and the coefficients of the polynomial $P(X) = \det(X \times Id - J)$ evaluated at the equilibrium depend smoothly on β_1 . Since we proved that (24) and (25) are true for $\beta_1 = 0$ by continuity the terms in the two conditions will remain strictly positive for β_1 small enough and by the Routh-Hurwitz criterion the equilibrium will be stable.

The only point remaining to be proved is 3b. Note that when $\beta_1 \rightarrow \infty$ the positive root A^f of the equation (12) converges to some quantity A^∞ , and $\beta(A^f) \rightarrow \infty$; moreover, we obtain from the definition of T^f that $\lim_{\beta_1 \rightarrow \infty} T^f = 0$ and $\lim_{\beta_1 \rightarrow \infty} (\beta(A^f)T^f) = \lim_{\beta_1 \rightarrow \infty} (\beta_1 T^f) = \frac{\delta(c+bA^\infty)}{\omega A^\infty}$. Consider the Jacobian matrix:

$$J = \begin{pmatrix} -\beta(A)V - \mu & 0 & -\beta(A)T & -\beta_1 TV \\ \beta(A)V & -\delta & \beta(A)T & \beta_1 TV \\ 0 & \omega & -(c+bA) & -bV \\ 0 & 0 & aA & aV - \sigma \end{pmatrix}. \quad (28)$$

Let us compute $P(X) = \det(XId - J) = \det(J - XId)$:

$$\begin{aligned} P(X) &= \begin{vmatrix} -\beta(A)V - \mu - X & 0 & -\beta(A)T & -\beta_1 TV \\ \beta(A)V & -\delta - X & \beta(A)T & \beta_1 TV \\ 0 & \omega & -X - (c+bA) & -bV \\ 0 & 0 & aA & -X \end{vmatrix} \\ &= \begin{vmatrix} -\mu - X & -\delta - X & 0 & 0 \\ \beta(A)V & -\delta - X & \beta(A)T & \beta_1 TV \\ 0 & \omega & -X - (c+bA) & -bV \\ 0 & 0 & aA & -X \end{vmatrix} \\ &= -(\mu + X) \begin{vmatrix} -\delta - X & \beta(A)T & \beta_1 TV \\ \omega & -X - (c+bA) & -bV \\ 0 & aA & -X \end{vmatrix} - \beta(A)V \begin{vmatrix} -\delta - X & 0 & 0 \\ \omega & -X - (c+bA) & -bV \\ 0 & aA & -X \end{vmatrix}. \end{aligned}$$

Thus the polynomial $P(X) = \det(XId - J)$ can be written, to first order in β_1 , as $P(X) = R(X) + \beta(A)V(X + \delta)(X^2 + X(c + bA) + aAbV)$, where $R(X)$ is a fourth order polynomial with leading term X^4 and coefficients independent of β_1 . Note that $(X + \delta)(X^2 + X(c + bA) + aAbV)$ is a stable polynomial. To finish the proof we invoke Lemma 1 below for $\psi = \beta(A)V$.

□

Lemma 1. *Let $Z_3 = \phi_3 X^3 + \phi_2 X^2 + \phi_1 X + \phi_0$ be a stable polynomial of order 3 with $\phi_3 > 0$ and $Z_4 = \varphi_4 X^4 + \varphi_3 X^3 + \varphi_2 X^2 + \varphi_1 X + \varphi_0$ a polynomial of order four with $\varphi_4 > 0$. Then, for ψ large enough the polynomial $Z_4(X) + \psi Z_3(X)$ is stable.*

Proof. Since $\phi_3 > 0$ using the reciprocal of the Routh-Hurwitz criterion all coefficients ϕ_k are strictly positive and $\phi_1 \phi_2 > \phi_0 \phi_3$. For ψ large enough this allows to check the Routh-Hurwitz criterion for the fourth order polynomial $Z_4(X) + \psi Z_3(X)$: the coefficients will be positive and the last remaining condition is $(\varphi_1 + \psi \phi_1)(\varphi_2 + \psi \phi_2)(\varphi_3 + \psi \phi_3) > (\varphi_0 + \psi \phi_0)(\varphi_3 + \psi \phi_3)^2 + (\varphi_1 + \psi \phi_1)\varphi_4^2$, which is satisfied for ψ large enough (leading term $(\phi_1 \phi_2 - \phi_0 \phi_3)\phi_3$ is positive). □

E Extended model including a latent phase

We present here a version of the main model (1)-(5) extended to take into account a latent phase of the cells. The interest of such a model is to give a finer description of all states of the attacked cells; this comes however at the price of requiring several more parameters (including the transition rate $\eta > 0$ from the latent to infected, virus-producing, cells). In practice the choice of the model depends on the outcomes of interest and available data to fit. In our case the data to fit was relatively scarce thus we kept the restricted model (1)-(5) for the numerical simulations. Denoting L the number of latent infected cells (i.e., cells already infected but not yet producing viruses) we can write this model as:

$$dT/dt = \Lambda - \mu T - \beta(A)VT \quad (29)$$

$$dL/dt = \beta(A)VT - \eta L - \mu L \quad (30)$$

$$dI/dt = \eta L - \delta I \quad (31)$$

$$dV/dt = \omega I - cV - bAV \quad (32)$$

$$dA/dt = aVA - \sigma A \quad (33)$$

$$\beta(A) = \beta_0 + \beta_1 A. \quad (34)$$

The model is illustrated in figure 8.




Figure 8: Graphical illustration of the flow in the model (29)-(34).